Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jan 23:11:1-11.
doi: 10.2174/1874613601711010001. eCollection 2017.

Clinical Outcomes of Tenofovir Versus Zidovudine-based Regimens Among People Living with HIV/AIDS: a Two Years Retrospective Cohort Study

Teshale Ayele  1 , Habtemu Jarso  2 , Girma Mamo  3
Affiliations

Clinical Outcomes of Tenofovir Versus Zidovudine-based Regimens Among People Living with HIV/AIDS: a Two Years Retrospective Cohort Study

Teshale Ayele et al. Open AIDS J. .

Abstract

Background: Tenofovir (TDF) based regimen is one of the first line agents that has been utilized routinely since 2013 in Ethiopia. Unfortunately, there is limited information regarding the Clinical outcomes and associated risk factors in this setting, where patients generally present late, have high rates of TB and other infectious conditions.

Methods: A two year retrospective cohort study was conducted from February 10/2015 to March 10/2015 at Jimma University Specialized Hospital. A total of 280 records were reviewed by including data from September 3, 2012 to July 31, 2014. Records were selected using a simple random sampling technique. Data was collected on socio-demographic, clinical and drug related variables. Data was analyzed using STATA 13.1. Kaplan-Meier and Cox regression were used to compare survival experience and identify independent predictors. Propensity score matching analysis was conducted to elucidate the average treatment effects of each regimen over opportunistic infections.

Results: Of 280 patients, 183(65.36%) were females and 93(33.32%) of females belong to Tenofovir group. Through 24 months analysis, TDF based regimen had a protective effect against death and opportunistic infections (OIs), (AHR=0.79, 95% CI [0.24, 2.62]) and (AHR=0.78, 95%CI [0.43, 1.4] respectively. The average treatment effect of TDF/3TC/EFV was (-71/1000, p=0.026), while it was (+114/1000, p=0.049) for AZT/3TC/EFV. However, TDF/3TC/NVP was associated with statistically insignificant morbidity reduction (-74/1000, p=0.377). Those with body mass-index (BMI) <18.5kg/m2 (AHR=3.21, 95%CI [0.93, 11.97]) had higher hazard of death. Absence of baseline prophylaxis (AHR=8.22, 95% CI [1.7, 39.77]), Cotrimoxazole prophylaxis alone (AHR=6.15, 95% CI [1.47, 26.67]) and BMI<18.5kg/m2 (AHR=2.06, 95% CI [1.14, 3.73]) had higher hazards of OIs.

Conclusion: The survival benefit of TDF based regimen was similar to AZT based regimen and therefore can be used as an alternative for HIV/AIDS patients in resource limited setups. However, since this study was not dealt with toxicity of the regimens, we recommend to conduct high quality design on this issue.

Keywords: Jimma University Specialize hospital; Tenofovir regimen; Treatment outcomes; Zidovudine regimen.

PubMed Disclaimer

Figures

Fig. (1)
Fig. (1)
Sample recruitment chart at JUSH; of patients attending ART clinic, February10 -March10, 2015.
Fig. (2)
Fig. (2)
Survival estimates for opportunistic infections among the cohort at JUSH, from February 10 to March 2015.
See this image and copyright information in PMC

References

    1. Tang M.W., Kanki P.J., Shafer R.W. A review of the virological efficacy of the 4 World Health Organization-recommended tenofovir-containing regimens for initial HIV therapy. Clin. Infect. Dis. 2012;54(6):862–875. doi: 10.1093/cid/cir1034. - DOI - PMC - PubMed
    1. Ruan Y., Xing H., Wang X., Tang H., Wang Z., Liu H., Su B., Wu J., Li H., Liao L., Li J., Wu J.W., Shao Y. Virologic outcomes of first-line HAART and associated factors among Chinese patients with HIV in three sentinel antiretroviral treatment sites. Trop. Med. Int. Health. 2010;15(11):1357–1363. doi: 10.1111/j.1365-3156.2010.02621.x. - DOI - PubMed
    1. Ford N., Calmy A. Improving first-line antiretroviral therapy in resource-limited settings. Curr. Opin. HIV AIDS. 2010;5(1):38–47. doi: 10.1097/COH.0b013e3283339b41. - DOI - PubMed
    1. Brinkman K. Stavudine in antiretroviral therapy: is this the end? AIDS. 2009;23(13):1727–1729. doi: 10.1097/QAD.0b013e32832d3c5e. - DOI - PubMed
    1. Birkus G., Hitchcock M.J., Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 2002;46(3):716–723. doi: 10.1128/AAC.46.3.716-723.2002. - DOI - PMC - PubMed

LinkOut - more resources